Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Erik J Groessl, Steven R Tally & Naomi Hillery. (2023) Cost-Effectiveness of Humidified High-Flow Therapy (HHFT) for COPD Patients on Long-Term Oxygen Therapy. ClinicoEconomics and Outcomes Research 15, pages 239-250.
Read now
Read now
Paola Rogliani, Luigino Calzetta, Mario Cazzola & Maria Gabriella Matera. (2016) Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. Expert Opinion on Drug Safety 15:8, pages 1133-1146.
Read now
Read now
Mario Cazzola, Luigino Calzetta, Paola Rogliani & Maria Gabriella Matera. (2016) The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Drug Discovery 11:7, pages 733-744.
Read now
Read now
Foruhar Moayeri, Ya-Seng (Arthur) Hsueh, Philip Clarke, Xinyang Hua & David Dunt. (2016) Health State Utility Value in Chronic Obstructive Pulmonary Disease (COPD); The Challenge of Heterogeneity: A Systematic Review and Meta-Analysis. COPD: Journal of Chronic Obstructive Pulmonary Disease 13:3, pages 380-398.
Read now
Read now
Thomas R. Einarson, Basil G. Bereza, T. Anders Nielsen, Jan Van Laer & Michiel E. H. Hemels. (2016) Systematic review of models used in economic analyses in moderate-to-severe asthma and COPD. Journal of Medical Economics 19:4, pages 319-355.
Read now
Read now
Thomas R. Einarson, Basil G. Bereza, T. Anders Nielsen & Michiel E. H. Hemels. (2015) Utilities for asthma and COPD according to category of severity: a comprehensive literature review. Journal of Medical Economics 18:7, pages 550-563.
Read now
Read now
Donald P Tashkin. (2014)
Roflumilast: the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD. Expert Opinion on Pharmacotherapy 15:1, pages 85-96.
Read now
Read now
Articles from other publishers (12)
Jia Liu, Xiaoning He & Jing Wu. (2022) Economic Evaluation of Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease in China Using a Semi-Markov Model. Applied Health Economics and Health Policy 20:5, pages 743-755.
Crossref
Crossref
Mohsen Sadatsafavi, Shahzad Ghanbarian, Amin Adibi, Kate Johnson, J. Mark FitzGerald, William Flanagan, Stirling Bryan & Don Sin. (2019) Development and Validation of the Evaluation Platform in COPD (EPIC): A Population-Based Outcomes Model of COPD for Canada. Medical Decision Making 39:2, pages 152-167.
Crossref
Crossref
Nguyen Xuan Thanh, Philip Jacobs, Jason Suggett, Andrew McIvor & Alan Kaplan. (2019) Cost-Effectiveness of the Aerobika® Oscillating Positive Expiratory Pressure Device in the Management of Chronic Obstructive Pulmonary Disease Exacerbations in Canada. Canadian Respiratory Journal 2019, pages 1-7.
Crossref
Crossref
Wouter Poortinga, Sarah E Rodgers, Ronan A Lyons, Pippa Anderson, Chris Tweed, Charlotte Grey, Shiyu Jiang, Rhodri Johnson, Alan Watkins & Thomas G Winfield. (2018) The health impacts of energy performance investments in low-income areas: a mixed-methods approach. Public Health Research 6:5, pages 1-182.
Crossref
Crossref
Martine Hoogendoorn, Talitha L. Feenstra, Yumi Asukai, Andrew H. Briggs, Ryan N. Hansen, Reiner Leidl, Nancy Risebrough, Yevgeniy Samyshkin, Margarethe Wacker & Maureen P.M.H. Rutten-van Mölken. (2017) External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting. Value in Health 20:3, pages 397-403.
Crossref
Crossref
Zafar Zafari, Stirling Bryan, Don D. Sin, Tania Conte, Rahman Khakban & Mohsen Sadatsafavi. (2017) A Systematic Review of Health Economics Simulation Models of Chronic Obstructive Pulmonary Disease. Value in Health 20:1, pages 152-162.
Crossref
Crossref
Simon van der Schans, Lucas M. A. Goossens, Melinde R. S. Boland, Janwillem W. H. Kocks, Maarten J. Postma, Job F. M. van Boven & Maureen P. M. H. Rutten-van Mölken. (2016) Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations. PharmacoEconomics 35:1, pages 43-63.
Crossref
Crossref
Foruhar Moayeri, Ya-Seng (Arthur) Hsueh, Philip Clarke & David Dunt. (2016) Do Model-Based Studies in Chronic Obstructive Pulmonary Disease Measure Correct Values of Utility? A Meta-Analysis. Value in Health 19:4, pages 363-373.
Crossref
Crossref
Karly P. Garnock-Jones. (2015) Roflumilast: A Review in COPD. Drugs 75:14, pages 1645-1656.
Crossref
Crossref
Pepijn VemerLucas M. A. GoossensMaureen P. M. H. Rutten-van Mölken. (2014) Not Simply More of the Same. Medical Decision Making 34:8, pages 1048-1058.
Crossref
Crossref
K. Suresh Babu, Jack A. Kastelik & Jaymin B. Morjaria. (2014) Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective. British Journal of Clinical Pharmacology 78:2, pages 282-300.
Crossref
Crossref
Martine Hoogendoorn, Talitha L. Feenstra, Yumi Asukai, Sixten Borg, Ryan N. Hansen, Sven-Arne Jansson, Yevgeniy Samyshkin, Margarethe Wacker, Andrew H. Briggs, Adam Lloyd, Sean D. Sullivan & Maureen P.M.H. Rutten-van Mölken. (2014) Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease: Cross-Model Comparison of Hypothetical Treatment Scenarios. Value in Health 17:5, pages 525-536.
Crossref
Crossref